• Samuel Chan, Nicole M Isbel, Carmel M Hawley, Scott B Campbell, Katrina L Campbell, Mark Morrison, Ross S Francis, E Geoffrey Playford, and David W Johnson.
• Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia. samuel.chan@uqconnect.edu.au.
• Medicina (Kaunas). 2019 Oct 4; 55 (10).

AbstractThe incidence of infectious complications, compared with the general population and the pre-transplant status of the recipient, increases substantially following kidney transplantation, causing significant morbidity and mortality. The potent immunosuppressive therapy given to prevent graft rejection in kidney transplant recipients results in an increased susceptibility to a wide range of opportunistic infections including bacterial, viral and fungal infections. Over the last five years, several advances have occurred that may have changed the burden of infectious complications in kidney transplant recipients. Due to the availability of direct-acting antivirals to manage donor-derived hepatitis C infection, this has opened the way for donors with hepatitis C infection to be considered in the donation process. In addition, there have been the development of medications targeting the growing burden of resistant cytomegalovirus, as well as the discovery of the potentially important role of the gastrointestinal microbiota in the pathogenesis of post-transplant infection. In this narrative review, we will discuss these three advances and their potential implications for clinical practice.

28 keywords...

hide…